ZNTL azenosertib advances in platinum-resistant ovarian cancer
Azenosertib’s key clinical trials in platinum-resistant ovarian cancer are progressing, supported by robust safety oversight and a validated biomarker strategy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ZNTL advances pivotal Azenosertib ovarian cancer trials with FDA support
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, citing a robust safety profile and a validated biomarker strategy. The company says FDA alignment is strong and highlights a differentiated oral option.